Bharat Parenterals witnessed a sharp 10% jump in its share price after its subsidiary, Innoxel Lifesciences, announced the successful completion of the European Union Good Manufacturing Practice (EU GMP) inspection. The audit was conducted by Belgium’s Federal Agency for Medicines and Health Products (FAMHP) at the company’s manufacturing facility between 24 and 28 November 2025.
According to the company, the inspection concluded with zero critical and zero major observations, underscoring the strength of Innoxel’s quality systems and its commitment to international compliance. The clean report reflects the firm’s robust manufacturing capabilities, advanced infrastructure, and consistent adherence to stringent global regulatory standards.
This milestone adds another layer of credibility to the company’s regulatory track record, especially after its earlier positive outcomes from USFDA inspections. With back-to-back successful audits from major global agencies, Bharat Parenterals is positioning itself as a reliable partner for regulated international markets. The market responded positively to this development, driving strong investor sentiment and lifting the stock sharply in today’s trade.
